Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study

QR Code

Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study

Abstract Background Tocilizumab is an IgG1 class recombinant humanized monoclonal antibody that directly inhibits the IL-6 receptor. Several randomized clinical trials have evaluated its safety and efficacy in patients with coronavirus disease 2019 (COVID-19), and these studies demonstrate conflicti...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Ohoud Aljuhani, Khalid Al Sulaiman, Adel Alshabasy, Khalid Eljaaly, Abdulrahman I. Al Shaya, Haytham Noureldeen, Mohammed Aboudeif, Bodoor Al Dosari, Amina Alkhalaf, Ghazwa B. Korayem, Muneera M. Aleissa, Hisham A. Badreldin, Shmeylan Al Harbi, Abdullah Alhammad, Ramesh Vishwakarma
Format:	article
Langue:	EN
Publié:	BMC 2021
Sujets:	COVID-19 SARS-Cov-2 Tocilizumab Secondary infection CRE Critically ill Infectious and parasitic diseases RC109-216
Accès en ligne:	https://doaj.org/article/c8d00252251f49ceb5ec2537a6f9c97e
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Tocilizumab-Induced Sweet Syndrome in a Patient With Polymyalgia Rheumatica
par: Federica Filippi, et autres
Publié: (2019)

Use of the rheumatic drug tocilizumab for treatment of SARS-CoV-2 patients
par: Bogna Grygiel-Górniak, et autres
Publié: (2021)

Safety and efficacy of tocilizumab for rheumatoid arthritis: a systematic review and metaanalysis of clinical trial studies
par: Amal Saki, et autres
Publié: (2021)

Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumab
par: Benucci M, et autres
Publié: (2016)

Case Report: Tocilizumab for Acute Kidney Graft Dysfunction in Patient Affected by COVID-19
par: Infante Barbara, et autres
Publié: (2021)

Tocilizumab in Systemic Juvenile Idiopathic Arthritis: Response Differs by Disease Duration at Medication Initiation and by Phenotype of Disease
par: Xin Yan, et autres
Publié: (2021)

A young girl with severe polyarteritis nodosa successfully treated with tocilizumab: a case report
par: Margaux Boistault, et autres
Publié: (2021)

Author Correction: Ascorbic acid as an adjunctive therapy in critically ill patients with COVID-19: a propensity score matched study
par: Khalid Al Sulaiman, et autres
Publié: (2021)

Ascorbic acid as an adjunctive therapy in critically ill patients with COVID-19: a propensity score matched study
par: Khalid Al Sulaiman, et autres
Publié: (2021)

Tocilizumab in refractory rheumatoid arthritis: long-term efficacy, safety, and tolerability beyond 2 years
par: Farah Z, et autres
Publié: (2016)

Real World Long-term Assessment of The Efficacy of Tocilizumab in Patients with COVID-19: Results From A Large De-identified Multicenter Electronic Health Record Dataset in the United States
par: Masayuki Nigo, et autres
Publié: (2021)

Effectiveness of Tocilizumab with and without Dexamethasone in Patients with Severe COVID-19: A Retrospective Study
par: Zarębska-Michaluk D, et autres
Publié: (2021)

Dynamic Contrast-Enhanced MRI Confirms Rapid And Sustained Improvement Of Rheumatoid Arthritis Induced By Tocilizumab Treatment: An Italian Multicentre Study
par: Cimmino MA, et autres
Publié: (2020)

The Use of Tocilizumab in Patients with COVID-19: A Systematic Review, Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Studies
par: Alberto Enrico Maraolo, et autres
Publié: (2021)

Risk factors of adverse outcome of COVID-19 and experience of Tocilizumab administration in patients on maintenance hemodialysis due to diabetic kidney disease
par: E. M. Zeltyn-Abramov, et autres
Publié: (2021)

Cre-loxP recombination vectors for promoter studies
par: Pedersen,Nina, et autres
Publié: (2007)

A Single-Center Retrospective Observational Study Evaluating the Favorable Predictive Factors for the Disease Control Time of Treatment with Tocilizumab in Patients of Rheumatoid Arthritis
par: Ishii N, et autres
Publié: (2021)

The impact of early target attainment of vancomycin in critically ill patients with confirmed Gram-positive infection: A retrospective cohort study
par: Khalid Al Sulaiman, et autres
Publié: (2021)

Appropriateness of Using Vitamin K for the Correction of INR Elevation Secondary to Hepatic Disease in Critically ill Patients: An Observational Study
par: Khalid Al Sulaiman, et autres
Publié: (2021)

Immunomodulation and Reduction of Thromboembolic Risk in Hospitalized COVID-19 Patients: Systematic Review and Meta-Analysis of Randomized Trials
par: Dimitrios Sagris, et autres
Publié: (2021)

Comprehensive Analysis of <named-content content-type="genus-species">Aspergillus nidulans</named-content> PKA Phosphorylome Identifies a Novel Mode of CreA Regulation
par: Liliane F. C. Ribeiro, et autres
Publié: (2019)

Sulfamoyl Heteroarylcarboxylic Acids as Promising Metallo-β-Lactamase Inhibitors for Controlling Bacterial Carbapenem Resistance
par: Jun-ichi Wachino, et autres
Publié: (2020)

Iron Acquisition and Siderophore Release by Carbapenem-Resistant Sequence Type 258 <named-content content-type="genus-species">Klebsiella pneumoniae</named-content>
par: Victoria I. Holden, et autres
Publié: (2018)

Real-world clinical outcomes of meropenem/vaborbactam for treatment of carbapenem-resistant Enterobacterales infections
par: Helen L. Zhang, et autres
Publié: (2021)

Intestinal Dysbiosis in Carriers of Carbapenem-Resistant <italic toggle="yes">Enterobacteriaceae</italic>
par: Hila Korach-Rechtman, et autres
Publié: (2020)

In Vitro Activity Comparison of Ceftazidime–Avibactam and Aztreonam–Avibactam Against Bloodstream Infections With Carbapenem-Resistant Organisms in China
par: Wei Yu, et autres
Publié: (2021)

Evaluation of the therapeutic regimen in COVID-19 in transplant patients: where do immunomodulatory and antivirals stand?
par: Mojtaba Shafiekhani, et autres
Publié: (2021)

Regulation of <italic toggle="yes">Aspergillus nidulans</italic> CreA-Mediated Catabolite Repression by the F-Box Proteins Fbx23 and Fbx47
par: Leandro José de Assis, et autres
Publié: (2018)

Giant Cell Arteritis: The Experience of Two Collaborative Referral Centers and an Overview of Disease Pathogenesis and Therapeutic Advancements
par: Dammacco R, et autres
Publié: (2020)

Therapeutic potential of anticoagulant therapy in association with cytokine storm inhibition in severe cases of COVID-19: A case report
par: Xu Qiancheng, et autres
Publié: (2021)

Creativity research journal
Publié: (1988)

Engineered Type Six Secretion Systems Deliver Active Exogenous Effectors and Cre Recombinase
par: Steven J. Hersch, et autres
Publié: (2021)

Not All That Is Gold Glitters: PV-IRES-Cre Mouse Line Shows Low Efficiency of Labeling of Parvalbumin Interneurons in the Perirhinal Cortex
par: Maximiliano José Nigro, et autres
Publié: (2021)

Effect of flaxseed on systemic inflammation and oxidative stress in diabetic rats with or without chronic kidney disease.
par: Mohammed Al Za'abi, et autres
Publié: (2021)

Collecting Duct-Specific CR6-Interacting Factor-1-Deletion Aggravates Renal Inflammation and Fibrosis Induced by Unilateral Ureteral Obstruction
par: Jin Young Jeong, et autres
Publié: (2021)

Hydrophobic Optimization of Functional Poly(TPAE-co-suberoyl chloride) for Extrahepatic mRNA Delivery following Intravenous Administration
par: Xueliang Yu, et autres
Publié: (2021)

Sport and International Relations: Qatari Soft Power and Foreign Policy Making
par: Noof Al-Dosari
Publié: (2021)

Major Cardiovascular Advances: Highlights from the 2019 American College of Cardiology Annual Scientific Session
par: Hisham A Badreldin, et autres
Publié: (2020)

ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically lll COVID-19 Patients
par: Eleni Karakike, et autres
Publié: (2021)

Clinical characteristics of patients with COVID-19 depending on the treatment received and the presence of type 2 diabetes mellitus
par: K. G. Lobanova, et autres
Publié: (2021)